Trial Profile
AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms MADIET
- 15 Jul 2020 Status changed from recruiting to completed.
- 12 Jun 2020 This trial has been completed in Greece according to European Clinical Trials Database record.
- 02 Apr 2018 New trial record